Eliem Therapeutics, Inc.
ELYM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,176 | $15,411 | $26,214 | $23,322 |
| G&A Expenses | $16,025 | $9,888 | $18,921 | $12,350 |
| SG&A Expenses | $16,025 | $9,888 | $18,921 | $12,350 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $51,819 | $0 | $0 | $0 |
| Operating Expenses | $82,020 | $37,408 | $45,135 | $35,672 |
| Operating Income | -$82,020 | -$21,466 | -$45,135 | -$35,672 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8,123 | -$13,653 | -$109 | -$11,808 |
| Pre-Tax Income | -$73,897 | -$35,119 | -$45,244 | -$47,480 |
| Tax Expense | $0 | $0 | $109 | $0 |
| Net Income | -$73,897 | -$35,119 | -$45,353 | -$47,480 |
| % Margin | – | – | – | – |
| EPS | -1.53 | -1.3 | -1.72 | -1.81 |
| % Growth | -17.7% | 24.4% | 5% | – |
| EPS Diluted | -1.53 | -1.3 | -1.72 | -1.81 |
| Weighted Avg Shares Out | 67,255 | 26,987 | 26,312 | 26,235 |
| Weighted Avg Shares Out Dil | 67,255 | 26,987 | 26,312 | 26,235 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $1,593 | $0 |
| Depreciation & Amortization | $0 | $21,466 | $45,135 | $35,672 |
| EBITDA | -$82,020 | -$13,653 | $1,484 | -$35,502 |
| % Margin | – | – | – | – |